Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.

Santana VM, Sahr N, Tatevossian RG, Jia S, Campagne O, Sykes A, Stewart CF, Furman WL, McGregor LM.

Cancer. 2020 Jan 22. doi: 10.1002/cncr.32722. [Epub ahead of print]

PMID:
31967673
2.

Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study.

Rao P, Segel JE, McGregor LM, Lengerich EJ, Drabick JJ, Miller B.

J Adolesc Young Adult Oncol. 2019 Oct 10. doi: 10.1089/jayao.2019.0045. [Epub ahead of print]

PMID:
31600095
3.

Preference for Deliberation and Perceived Usefulness of Standard- and Narrative-Style Leaflet Designs: Implications for Equitable Cancer-Screening Communication.

Robb KA, Gatting LP, von Wagner C, McGregor LM.

Ann Behav Med. 2019 Oct 9. pii: kaz039. doi: 10.1093/abm/kaz039. [Epub ahead of print]

PMID:
31595299
4.

Predictors of intention translation in flexible sigmoidoscopy screening for colorectal cancer.

von Wagner C, Bonello B, Stoffel ST, Skrobanski H, Kerrison R, McGregor LM.

Health Psychol. 2019 Dec;38(12):1083-1095. doi: 10.1037/hea0000793. Epub 2019 Sep 26.

PMID:
31556658
5.

The impact of descriptive norms on motivation to participate in cancer screening - Evidence from online experiments.

von Wagner C, Hirst Y, Waller J, Ghanouni A, McGregor LM, Kerrison RS, Verstraete W, Vlaev I, Sieverding M, Stoffel ST.

Patient Educ Couns. 2019 Sep;102(9):1621-1628. doi: 10.1016/j.pec.2019.04.001. Epub 2019 Apr 4.

6.

Using specialist screening practitioners (SSPs) to increase uptake of bowel scope (flexible sigmoidoscopy) screening: results of a feasibility single-stage phase II randomised trial.

McGregor LM, Skrobanski H, Ritchie M, Berkman L, Miller H, Freeman M, Patel N, Morris S, Rees C, von Wagner C.

BMJ Open. 2019 Feb 15;9(2):e023801. doi: 10.1136/bmjopen-2018-023801.

7.

Rapid review of factors associated with flexible sigmoidoscopy screening use.

Kerrison RS, von Wagner C, Green T, Gibbins M, Macleod U, Hughes M, Rees CJ, Duffy S, McGregor LM.

Prev Med. 2019 Mar;120:8-18. doi: 10.1016/j.ypmed.2018.12.018. Epub 2018 Dec 28. Review.

8.

Testing active choice for screening practitioner's gender in endoscopy among disinclined women: An online experiment.

Stoffel ST, Hirst Y, Ghanouni A, McGregor LM, Kerrison R, Verstraete W, Gallagher A, Waller J, von Wagner C.

J Med Screen. 2019 Jun;26(2):98-103. doi: 10.1177/0969141318806322. Epub 2018 Nov 14.

9.

Use of Two Self-referral Reminders and a Theory-Based Leaflet to Increase the Uptake of Flexible Sigmoidoscopy in the English Bowel Scope Screening Program: Results From a Randomized Controlled Trial in London.

Kerrison RS, McGregor LM, Counsell N, Marshall S, Prentice A, Isitt J, Rees CJ, von Wagner C.

Ann Behav Med. 2018 Oct 22;52(11):941-951. doi: 10.1093/abm/kax068.

10.

Barriers to bowel scope (flexible sigmoidoscopy) screening: a comparison of non-responders, active decliners and non-attenders.

von Wagner C, Bonello B, Stoffel S, Skrobanski H, Freeman M, Kerrison RS, McGregor LM.

BMC Public Health. 2018 Oct 5;18(1):1161. doi: 10.1186/s12889-018-6071-8.

11.

Using primary care-based paper and telephone interventions to increase uptake of bowel scope screening in Yorkshire: a protocol of a randomised controlled trial.

McGregor LM, Kerrison RS, Green T, Macleod U, Hughes M, Gibbins M, Morris S, Rees C, von Wagner C.

BMJ Open. 2018 Jul 28;8(7):e024616. doi: 10.1136/bmjopen-2018-024616.

12.

Persuasion, Adaptation, and Double Identity: Qualitative Study on the Psychological Impact of a Screen-Detected Colorectal Cancer Diagnosis.

McGregor LM, Tookey S, Raine R, von Wagner C, Black G.

Gastroenterol Res Pract. 2018 Jun 7;2018:1275329. doi: 10.1155/2018/1275329. eCollection 2018.

13.

Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.

Smith SG, Wardle J, Atkin W, Raine R, McGregor LM, Vart G, Morris S, Duffy SW, Moss S, Hackshaw A, Halloran S, Kralj-Hans I, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas M, Counsell N, von Wagner C.

BMC Cancer. 2017 Aug 14;17(1):543. doi: 10.1186/s12885-017-3512-1.

14.

Discovery of a Covalent Kinase Inhibitor from a DNA-Encoded Small-Molecule Library × Protein Library Selection.

Chan AI, McGregor LM, Jain T, Liu DR.

J Am Chem Soc. 2017 Aug 2;139(30):10192-10195. doi: 10.1021/jacs.7b04880. Epub 2017 Jul 20.

15.

Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes.

McGregor LM, Jenkins ML, Kerwin C, Burke JE, Shokat KM.

Biochemistry. 2017 Jun 27;56(25):3178-3183. doi: 10.1021/acs.biochem.7b00271. Epub 2017 Jun 16.

16.

Improving uptake of flexible sigmoidoscopy screening: a randomized trial of nonparticipant reminders in the English Screening Programme.

Kerrison RS, McGregor LM, Marshall S, Isitt J, Counsell N, Rees CJ, von Wagner C.

Endoscopy. 2017 Jan;49(1):35-43. doi: 10.1055/s-0042-118452. Epub 2016 Dec 20.

17.

Using Specialist Screening Practitioners (SSPs) to increase uptake of the Bowel Scope (Flexible Sigmoidoscopy) Screening Programme: a study protocol for a feasibility single-stage phase II trial.

McGregor LM, Skrobanski H, Miller H, Ritchie M, Berkman L, Morris S, Rees C, von Wagner C.

Pilot Feasibility Stud. 2016 Sep 14;2:54. eCollection 2016.

18.

A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.

Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW.

Br J Cancer. 2016 Dec 6;115(12):1479-1486. doi: 10.1038/bjc.2016.365. Epub 2016 Nov 22.

19.

What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population.

Vrinten C, McGregor LM, Heinrich M, von Wagner C, Waller J, Wardle J, Black GB.

Psychooncology. 2017 Aug;26(8):1070-1079. doi: 10.1002/pon.4287. Epub 2016 Oct 6. Review.

20.

Inequalities in cancer screening participation: examining differences in perceived benefits and barriers.

Smith SG, McGregor LM, Raine R, Wardle J, von Wagner C, Robb KA.

Psychooncology. 2016 Oct;25(10):1168-1174. doi: 10.1002/pon.4195. Epub 2016 Jul 14.

21.

Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial.

McGregor LM, von Wagner C, Atkin W, Kralj-Hans I, Halloran SP, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Thomas MC, Smith SG, Vart G, Howe R, Counsell N, Hackshaw A, Morris S, Duffy SW, Raine R, Wardle J.

Gastroenterol Res Pract. 2016;2016:3670150. doi: 10.1155/2016/3670150. Epub 2016 Mar 16.

22.

Use of a 12 months' self-referral reminder to facilitate uptake of bowel scope (flexible sigmoidoscopy) screening in previous non-responders: a London-based feasibility study.

Kerrison RS, McGregor LM, Marshall S, Isitt J, Counsell N, Wardle J, von Wagner C.

Br J Cancer. 2016 Mar 29;114(7):751-8. doi: 10.1038/bjc.2016.43. Epub 2016 Mar 15.

23.

Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.

Raine R, Duffy SW, Wardle J, Solmi F, Morris S, Howe R, Kralj-Hans I, Snowball J, Counsell N, Moss S, Hackshaw A, von Wagner C, Vart G, McGregor LM, Smith SG, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Atkin W.

Br J Cancer. 2016 Feb 2;114(3):321-6. doi: 10.1038/bjc.2015.413. Epub 2016 Jan 7.

24.

Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.

Wardle J, von Wagner C, Kralj-Hans I, Halloran SP, Smith SG, McGregor LM, Vart G, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Counsell N, Morris S, Duffy SW, Hackshaw A, Moss S, Atkin W, Raine R.

Lancet. 2016 Feb 20;387(10020):751-9. doi: 10.1016/S0140-6736(15)01154-X. Epub 2015 Dec 9.

25.

Understanding low colorectal cancer screening uptake in South Asian faith communities in England--a qualitative study.

Palmer CK, Thomas MC, McGregor LM, von Wagner C, Raine R.

BMC Public Health. 2015 Oct 1;15:998. doi: 10.1186/s12889-015-2334-9.

26.

Uptake of Bowel Scope (Flexible Sigmoidoscopy) Screening in the English National Programme: the first 14 months.

McGregor LM, Bonello B, Kerrison RS, Nickerson C, Baio G, Berkman L, Rees CJ, Atkin W, Wardle J, von Wagner C.

J Med Screen. 2016 Jun;23(2):77-82. doi: 10.1177/0969141315604659. Epub 2015 Sep 20.

PMID:
26387824
27.

An aptamer-functionalized chemomechanically modulated biomolecule catch-and-release system.

Shastri A, McGregor LM, Liu Y, Harris V, Nan H, Mujica M, Vasquez Y, Bhattacharya A, Ma Y, Aizenberg M, Kuksenok O, Balazs AC, Aizenberg J, He X.

Nat Chem. 2015 May;7(5):447-54. doi: 10.1038/nchem.2203. Epub 2015 Mar 23.

PMID:
25901824
28.

The impact of supplementary narrative-based information on colorectal cancer screening beliefs and intention.

McGregor LM, von Wagner C, Vart G, Yuen WC, Raine R, Wardle J, Robb KA.

BMC Cancer. 2015 Mar 21;15:162. doi: 10.1186/s12885-015-1167-3.

29.

Novel selection methods for DNA-encoded chemical libraries.

Chan AI, McGregor LM, Liu DR.

Curr Opin Chem Biol. 2015 Jun;26:55-61. doi: 10.1016/j.cbpa.2015.02.010. Epub 2015 Feb 24. Review.

30.

A DNA-based molecular probe for optically reporting cellular traction forces.

Blakely BL, Dumelin CE, Trappmann B, McGregor LM, Choi CK, Anthony PC, Duesterberg VK, Baker BM, Block SM, Liu DR, Chen CS.

Nat Methods. 2014 Dec;11(12):1229-32. doi: 10.1038/nmeth.3145. Epub 2014 Oct 12.

31.

Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF, Santana V, McGregor LM.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1191-8. doi: 10.1007/s00280-014-2593-7. Epub 2014 Sep 26.

32.

Reclaiming their lives: the decision-making process in living liver donation--an interpretative phenomenological case study analysis of one couple.

McGregor LM, Dickson A, Flowers P, Hayes PC, O'Carroll RE.

Psychol Health. 2014;29(12):1373-87. doi: 10.1080/08870446.2014.940950. Epub 2014 Aug 7.

33.

Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.

Lam CG, Furman WL, Wang C, Spunt SL, Wu J, Ivy P, Santana VM, McGregor LM.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e13-8. doi: 10.1097/MPH.0000000000000186.

34.

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM.

J Clin Oncol. 2014 May 10;32(14):1445-52. doi: 10.1200/JCO.2013.50.4423. Epub 2014 Apr 7.

35.

Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.

Federico SM, Allewelt HB, Spunt SL, Hudson MM, Wu J, Billups CA, Jenkins J, Santana VM, Furman WL, McGregor LM.

J Pediatr Hematol Oncol. 2015 Jan;37(1):e6-e12. doi: 10.1097/MPH.0000000000000148.

36.

Identification of ligand-target pairs from combined libraries of small molecules and unpurified protein targets in cell lysates.

McGregor LM, Jain T, Liu DR.

J Am Chem Soc. 2014 Feb 26;136(8):3264-70. doi: 10.1021/ja412934t. Epub 2014 Feb 17.

37.

Repeat nephron-sparing surgery for children with bilateral Wilms tumor.

Kieran K, Williams MA, McGregor LM, Dome JS, Krasin MJ, Davidoff AM.

J Pediatr Surg. 2014 Jan;49(1):149-53. doi: 10.1016/j.jpedsurg.2013.09.048. Epub 2013 Oct 5.

PMID:
24439600
38.

Facilitators and barriers to help-seeking for breast and cervical cancer symptoms: a qualitative study with an ethnically diverse sample in London.

Marlow LA, McGregor LM, Nazroo JY, Wardle J.

Psychooncology. 2014 Jul;23(7):749-57. doi: 10.1002/pon.3464. Epub 2013 Dec 19.

39.

Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor.

Kieran K, Williams MA, Dome JS, McGregor LM, Krasin MJ, Davidoff AM.

J Pediatr Surg. 2013 Jul;48(7):1481-5. doi: 10.1016/j.jpedsurg.2013.02.033.

PMID:
23895958
40.

Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model.

Hartwich JE, Orr WS, Ng CY, Spence Y, McLaughlin JM, Furman WL, McGregor LM, Davidoff AM.

J Pediatr Surg. 2013 Jan;48(1):47-55. doi: 10.1016/j.jpedsurg.2012.10.043.

41.

Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM.

Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8. Erratum in: Clin Cancer Res. 2013 Apr 1;19(7):1914.

42.

Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma.

Pai Panandiker AS, Beltran C, Billups CA, McGregor LM, Furman WL, Davidoff AM.

Pediatr Blood Cancer. 2013 May;60(5):761-5. doi: 10.1002/pbc.24350. Epub 2012 Sep 28.

PMID:
23024112
43.

The promotion of HL-1 cardiomyocyte beating using anisotropic collagen-GAG scaffolds.

Gonnerman EA, Kelkhoff DO, McGregor LM, Harley BA.

Biomaterials. 2012 Dec;33(34):8812-21. doi: 10.1016/j.biomaterials.2012.08.051. Epub 2012 Sep 12.

PMID:
22979989
44.

The influence of health literacy on comprehension of a colonoscopy preparation information leaflet.

Smith SG, von Wagner C, McGregor LM, Curtis LM, Wilson EA, Serper M, Wolf MS.

Dis Colon Rectum. 2012 Oct;55(10):1074-80.

45.

Living organ donation: the effect of message frame on an altruistic behaviour.

McGregor LM, Ferguson E, O'Carroll RE.

J Health Psychol. 2012 Sep;17(6):821-32. doi: 10.1177/1359105311423862. Epub 2011 Nov 21.

PMID:
22104662
46.

Isolated subcutaneous metastasis of osteosarcoma 5 years after initial diagnosis.

Fernandez-Pineda I, Bahrami A, Green JF, McGregor LM, Davidoff AM, Sandoval JA.

J Pediatr Surg. 2011 Oct;46(10):2029-31. doi: 10.1016/j.jpedsurg.2011.06.011. Review.

PMID:
22008346
47.

A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcoma.

Debelenko LV, McGregor LM, Shivakumar BR, Dorfman HD, Raimondi SC.

Genes Chromosomes Cancer. 2011 Dec;50(12):1054-62. doi: 10.1002/gcc.20923. Epub 2011 Aug 24.

PMID:
21987447
48.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM.

Invest New Drugs. 2012 Aug;30(4):1660-70. doi: 10.1007/s10637-011-9724-3. Epub 2011 Jul 28.

49.

Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C.

Pediatr Blood Cancer. 2012 Mar;58(3):372-9. doi: 10.1002/pbc.23075. Epub 2011 Apr 20.

50.

Interaction-dependent PCR: identification of ligand-target pairs from libraries of ligands and libraries of targets in a single solution-phase experiment.

McGregor LM, Gorin DJ, Dumelin CE, Liu DR.

J Am Chem Soc. 2010 Nov 10;132(44):15522-4. doi: 10.1021/ja107677q.

Supplemental Content

Loading ...
Support Center